EverGlade Insights Blog
Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining...
Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President...
A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an...
Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army...
Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure....
Key Takeaways from the April 2025 Executive Order On April 2, 2025, President Trump issued an Executive Order titled “Modernizing Defense Acquisitions and Spurring Innovation in the Defense Industrial Base.” This directive signals a major...